Evidence map›Paper›PMID 27605183›Full record

ArticleMicroarrays (Basel, Switzerland)2013

Expanding the Diversity of Imaging-Based RNAi Screen Applications Using Cell Spot Microarrays.

Juha K Rantala, Sunjong Kwon, James Korkola, Joe W Gray

Abstract read
In one paragraph

Article in Microarrays (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.Laboratory investigation; a journal of technical methods and pathology · 2015
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Juha K RantalaDepartment of Biomedical Engineering and Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA. rantala@ohsu.edu.
Sunjong KwonDepartment of Biomedical Engineering and Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA. kwons@ohsu.edu.
James KorkolaDepartment of Biomedical Engineering and Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA. korkola@ohsu.edu.
Joe W GrayDepartment of Biomedical Engineering and Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA. grayjo@ohsu.edu.

Funding

Tissue and Outcomes CoreP50CA058207 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRAY, JOE W. · 1992 to 2012
$32.7M
Systems-Based Predictions of Responses to Cancer TherapyU54CA112970 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI GRAY, JOE W. · 2004 to 2014
$27.1M
NCI NIH HHS P50 CA058207NCI NIH HHS U54 CA112970
6 · The paper itself

Abstract

Over the past decade, great strides have been made in identifying gene aberrations and deregulated pathways that are associated with specific disease states. These association studies guide experimental studies aimed at identifying the aberrant genes and networks that cause the disease states. This requires functional manipulation of these genes and networks in laboratory models of normal and diseased cells. One approach is to assess molecular and biological responses to high-throughput RNA interference (RNAi)-induced gene knockdown. These responses can be revealed by immunofluorescent staining for a molecular or cellular process of interest and quantified using fluorescence image analysis. These applications are typically performed in multiwell format, but are limited by high reagent costs and long plate processing times. These limitations can be mitigated by analyzing cells grown in cell spot microarray (CSMA) format. CSMAs are produced by growing cells on small (~200 mm diameter) spots with each spot carrying an siRNA with transfection reagent. The spacing between spots is only a few hundred micrometers, thus thousands of cell spots can be arranged on a single cell culture surface. These high-density cell cultures can be immunofluorescently stained with minimal reagent consumption and analyzed quickly using automated fluorescence microscopy platforms. This review covers basic aspects of imaging-based CSMA technology, describes a wide range of immunofluorescence assays that have already been implemented successfully for CSMA screening and suggests future directions for advanced RNAi screening experiments.

Indexed as

cell spot microarrayshigh-throughput screeningimage cytometryquantitative immunofluorescence assaysRNA interference

Identifiers

PMID27605183
PMCPMC5003478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.